Safety and efficacy of the therapeutic DNA-based vaccine VB10.16 in combination with atezolizumab in persistent, recurrent or metastatic HPV16-positive cervical cancer: a multicenter, single-arm phase 2a study
Journal for ImmunoTherapy of Cancer · 2025-01 · 13 (1) · e010827
DOI: 10.1136/jitc-2024-010827 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 07.01.2025. Verfasst von Peter Hillemanns und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology and Obstetrics, Hannover Medical School, Hannover, Germany. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Antibodies, Monoclonal, Humanized, Human papillomavirus 16, Vaccines, DNA. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Norwegian Skattefunn R&D tax deduction program, F. Hoffmann-La Roche, Nykode Therapeutics.
Abstract (Originalsprache)
Background
Second-line treatment options for persistent, recurrent or metastatic (r/m) cervical cancer are limited. We investigated the safety, efficacy, and immunogenicity of the therapeutic DNA-based vaccine VB10.16 combined with the immune checkpoint inhibitor atezolizumab in patients with human papillomavirus (HPV)16-positive r/m cervical cancer. Patients and methods This multicenter, single-arm, phase 2a study ( NCT04405349 , registered 26 May 2020) enrolled adult patients with persistent, r/m HPV16-positive cervical cancer. Patients received 3 mg VB10.16 (every 3 weeks (Q3W) for 12 weeks, hereafter every 6 weeks) combined with 1,200 mg atezolizumab (Q3W) for 48 weeks in total with a 12-month follow-up. The primary endpoints were incidence and severity of adverse events (AEs) and objective response rate (ORR; Response Evaluation Criteria in Solid Tumor V.1.1). ORR was assessed in the efficacy population, being all response-evaluable patients who received any administration of VB10.16 and atezolizumab and had at least one post-baseline imaging assessment.
Results
Between June 16, 2020, and January 25, 2022, 52 patients received at least one administration of study treatment. Of these, 47 patients had a minimum of one post-baseline tumor assessment. The median follow-up time for survival was 11.7 months. AEs related to VB10.16 were non-serious and mainly mild injection site reactions (9 of 52 patients). There were no signs of new toxicities other than what was already described with atezolizumab. ORR was 19.1% (95% CI 9.1% to 33.3%). Median duration of response was not reached (n.r.) (95% CI 2.2 to n.r.), median progression-free survival was 4.1 months (95% CI 2.1 to 6.2), and median overall survival was 21.3 months (95% CI 8.5 to n.r.). In programmed death-ligand 1 (PD-L1)-positive patients (n=24), ORR was 29.2% (95% CI 12.6 to 51.1). HPV16-specific T-cell responses were analyzed in 36 of 47 patients with an increase observed in 22/36 (61%).
Conclusions
The therapeutic DNA-based vaccine VB10.16 combined with atezolizumab was safe and well tolerated showing a promising clinically meaningful efficacy with durable responses in patients with persistent, r/m HPV16-positive cervical cancer, especially if PD-L1-positive.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynecology and Obstetrics, Hannover Medical School, Hannover, Germany.
- Department of Obstetrics and Gynecology, Bulovka University Hospital Na Bulovce Budinova 67/2, Prague, Czech Republic.
- Center hospital de l'Ardenne, Libramont, Belgium.
- Medical Oncology, University Hospital Ghent, Gent, Flanders, Belgium.
- University Clinic Saint-Luc, Bruxelles, Belgium.
- University Hospital Kralovske Vinohrady, Praha, Czech Republic.
Förderung
- Norwegian Skattefunn R&D tax deduction program
- F. Hoffmann-La Roche
- Nykode Therapeutics
Zitieren
APA
Hillemanns, P., Zikan, M., Forget, F., Denys, H. G., Baurain, J. F., Rob, L., Woelber, L., Blecharz, P., Bidzinski, M., Chovanec, J., Marmé, F., Link, T., Dannecker, C., Rosholm, A., Berg, K. C. G., Oliveri, R. S., Lindemann, K., VB C-02 investigators, & VB C-02 study (2025). Safety and efficacy of the therapeutic DNA-based vaccine VB10.16 in combination with atezolizumab in persistent, recurrent or metastatic HPV16-positive cervical cancer: a multicenter, single-arm phase 2a study. Journal for ImmunoTherapy of Cancer, 13(1), e010827. https://doi.org/10.1136/jitc-2024-010827
Vancouver
Hillemanns P, Zikan M, Forget F, Denys HG, Baurain JF, Rob L, et al. Safety and efficacy of the therapeutic DNA-based vaccine VB10.16 in combination with atezolizumab in persistent, recurrent or metastatic HPV16-positive cervical cancer: a multicenter, single-arm phase 2a study. Journal for ImmunoTherapy of Cancer. 2025;13(1):e010827. doi:10.1136/jitc-2024-010827
BibTeX
@article{Hillemanns2025,
author = {Hillemanns, Peter and Zikan, Michal and Forget, Frédéric and Denys, Hannelore G and Baurain, Jean-Francois and Rob, Lukas and Woelber, Linn and Blecharz, Pawel and Bidzinski, Mariusz and Chovanec, Josef and Marmé, Frederik and Link, Theresa and Dannecker, Christian and Rosholm, Anders and Berg, Kaja C G and Oliveri, Roberto S and Lindemann, Kristina and VB C-02 investigators, VB C-02 investigators and VB C-02 study, VB C-02 study},
title = {Safety and efficacy of the therapeutic DNA-based vaccine VB10.16 in combination with atezolizumab in persistent, recurrent or metastatic HPV16-positive cervical cancer: a multicenter, single-arm phase 2a study},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2025},
volume = {13},
number = {1},
pages = {e010827},
doi = {10.1136/jitc-2024-010827}
}
EUVIMED